fbpx

Tabula Rasa HealthCare to Acquire DoseMe

Tabula Rasa HealthCare to Acquire DoseMe
4 Dec 2018 Latest News

DoseMe, the first company in the world to design a precision dosing platform – DoseMeRx – specifically developed for clinical practice today announced it will be acquired by Tabula Rasa HealthCare, Inc (NASDAQ:TRHC) a healthcare technology company advancing the field of medication safety.

Tabula Rasa HealthCare (“TRHC”) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations

“TRHC is the leader in medication risk management and the opportunity for us to leverage that expertise and bring together the science and technology of our two organizations is very impactful for providers and patients around the world,” said Charles Cornish, CEO, DoseMe.

“With DoseMe’s state-of-the-art decision support tool combined with our ability to predict and prevent harmful drug interactions through tools such as the MRM Matrix®, we are now able to offer hospitals a broader range of protection against adverse drug events, the fourth leading cause of death in the US,” said TRHC Chairman and CEO, Calvin H. Knowlton, Ph.D. “Together, we can power the shift to precision prescribing, tailoring medication to meet individual needs and tolerances, which will have a profound impact on safety, quality, and costs, such as medication-related increased hospital length-of-stay.”

To view the full press release visit TRHC latest news

 

About DoseMeRx

DoseMeRx is a precision dosing software designed for healthcare practitioners that uses Bayesian dosing methods to predict the optimal dose of drugs monitored by Therapeutic Drug Monitoring. It is unique support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, genotype (if available) and exact patient responses to the drug dosed (via drug concentrations) to guide dose optimization. Its simplicity and portability means Bayesian dosing benefits can be brought to every bedside. Try the full DoseMeRx platform including all drug packages free for 14 days.

Back to News

HIPAA Privacy Statement | Privacy policy | DoseMe & the GDPR | Copyright © 2012 - 2018 DoseMe Pty Ltd. All Rights Reserved.
DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.